ctDNA as a novel and promising approach for cancer diagnosis

a focus on hepatocellular carcinoma

Authors

  • Negin Biglari Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran https://orcid.org/0000-0001-8304-3038
  • Mohammad Sadegh Soltani-Zangbar Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran https://orcid.org/0000-0003-3960-5712
  • Jamal Mohammadian School of Advanced Medical Science, Tabriz University of Medical Sciences, Tabriz, Iran https://orcid.org/0000-0003-2363-7138
  • Amir Mehdizadeh Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. E-mail: mehdizadeha@tbzmed.ac.ir https://orcid.org/0000-0002-3029-4172
  • Khadijeh Abbasi Department of Biochemistry and Clinical Laboratories, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran https://orcid.org/0000-0003-1368-5304

DOI:

https://doi.org/10.17179/excli2023-6277

Keywords:

ctDNA, hepatocellular carcinoma, cancer diagnosis, screening biomarkers, ctDNA detection

Abstract

Hepatocellular carcinoma (HCC) is one of the most prevalent forms of cancer worldwide. Therefore, it is essential to diagnose and treat HCC patients promptly. As a novel discovery, circulating tumor DNA (ctDNA) can be used to analyze the tumor type and the cancer location. Additionally, ctDNA assists the cancer stage determination, which enables medical professionals to provide patients with the most appropriate treatment. This review will discuss the HCC-related mutated genes diagnosed by ctDNA. In addition, we will introduce the different and the most appropriate ctDNA diagnosis approaches based on the facilities.

Downloads

Published

2023-08-03

How to Cite

Biglari, N., Soltani-Zangbar, M. S., Mohammadian, J., Mehdizadeh, A., & Abbasi, K. (2023). ctDNA as a novel and promising approach for cancer diagnosis: a focus on hepatocellular carcinoma. EXCLI Journal, 22, 752–780. https://doi.org/10.17179/excli2023-6277

Issue

Vol. 22 (2023)

Section

Review articles

Categories

License

Copyright (c) 2023 Negin Biglari, Mohammad Sadegh Soltani-Zangbar, Jamal Mohammadian, Amir Mehdizadeh, Khadijeh Abbasi

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish in this journal agree to the following terms:

  • The authors keep the copyright and grant the journal the right of first publication under the terms of the Creative Commons Attribution license, CC BY 4.0. This licencse permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.
  • The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
  • Because the advice and information in this journal are believed to be true and accurate at the time of publication, neither the authors, the editors, nor the publisher accept any legal responsibility for any errors or omissions presented in the publication. The publisher makes no guarantee, express or implied, with respect to the material contained herein.
  • The authors can enter into additional contracts for the non-exclusive distribution of the journal's published version by citing the initial publication in this journal (e.g. publishing in an institutional repository or in a book).

Most read articles by the same author(s)